395 related articles for article (PubMed ID: 23718260)
21. Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process?
Einbinder Y; Siboni A; Zaidenstein S; Cohen-Hagai K; Benchetrit S; Zitman-Gal T
Nephrology (Carlton); 2022 Jan; 27(1):104-108. PubMed ID: 34611952
[TBL] [Abstract][Full Text] [Related]
22. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.
Redahan L; Davenport A
J Nephrol; 2016 Jun; 29(3):427-434. PubMed ID: 26616639
[TBL] [Abstract][Full Text] [Related]
23. A high peritoneal large pore fluid flux causes hypoalbuminaemia and is a risk factor for death in peritoneal dialysis patients.
Heaf JG; Sarac S; Afzal S
Nephrol Dial Transplant; 2005 Oct; 20(10):2194-201. PubMed ID: 16030031
[TBL] [Abstract][Full Text] [Related]
24. Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan.
Kawanishi H; Fujimori A; Tsuchida K; Takemoto Y; Tomo T; Minakuchi J; Yamamoto T; Kim M; Numata A; Choh S; Naito H;
Adv Perit Dial; 2005; 21():134-8. PubMed ID: 16686304
[TBL] [Abstract][Full Text] [Related]
25. Prothrombin fragment 1 + 2 (F1 + 2) in effluent is a useful marker for peritoneal permeability in peritoneal dialysis patients using neutral dialysate.
Sakurada T; Kojima S; Oishi D; Koitabashi K; Miyamoto M; Shirai S; Shibagaki Y; Yasuda T; Sato T; Kimura K
Adv Perit Dial; 2011; 27():2-5. PubMed ID: 22073819
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
Parikova A; Zweers MM; Struijk DG; Krediet RT
Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
[TBL] [Abstract][Full Text] [Related]
27. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
28. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.
Zweers MM; Struijk DG; Smit W; Krediet RT
J Lab Clin Med; 2001 Feb; 137(2):125-32. PubMed ID: 11174469
[TBL] [Abstract][Full Text] [Related]
30. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
31. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?
Martikainen TA; Teppo AM; Grönhagen-Riska C; Ekstrand AV
Perit Dial Int; 2005; 25(5):453-60. PubMed ID: 16178478
[TBL] [Abstract][Full Text] [Related]
32. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
[TBL] [Abstract][Full Text] [Related]
33. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
[TBL] [Abstract][Full Text] [Related]
34. Does a high peritoneal transport rate reflect a state of chronic inflammation?
Wang T; Heimbürger O; Cheng HH; Bergström J; Lindholm B
Perit Dial Int; 1999; 19(1):17-22. PubMed ID: 10201336
[TBL] [Abstract][Full Text] [Related]
35. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.
Passadakis P; Panagoutsos S; Thodis E; Tsivara I; Sopassi F; Kartali S; Vargemezis V
Adv Perit Dial; 1999; 15():40-4. PubMed ID: 10682070
[TBL] [Abstract][Full Text] [Related]
37. Dialysate vascular endothelial growth factor is an independent determinant of serum albumin levels and predicts future withdrawal from peritoneal dialysis in uremic patients.
Hazama T; Fukami K; Yamagishi S; Kusumoto T; Sakai K; Adachi T; Sonoda K; Kasuga S; Ueda S; Okuda S
Ther Apher Dial; 2014 Oct; 18(5):391-7. PubMed ID: 24251735
[TBL] [Abstract][Full Text] [Related]
38. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis?
Cueto-Manzano AM; Rojas-Campos E; Martínez-Ramírez HR; Valera-González I; Medina M; Monteón F; Ruiz N; Becerra M; Palomeque MA; Cortés-Sanabria L
Perit Dial Int; 2006; 26(3):341-8. PubMed ID: 16722027
[TBL] [Abstract][Full Text] [Related]
39. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport.
Stompór T; Zdzienicka A; Motyka M; Dembińska-Kieć A; Davies SJ; Sulowicz W
Perit Dial Int; 2002; 22(6):670-6. PubMed ID: 12556068
[TBL] [Abstract][Full Text] [Related]
40. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
